Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs MB 107 (Primary) ; Busulfan; Palifermin
- Indications Immunodeficiency disorders; X-linked genetic disorders
- Focus Pharmacogenomic; Therapeutic Use
- 09 Dec 2019 Results published in Mustang Bio Media Release
- 09 Dec 2019 According to a Mustang Bio media release, data from the trial were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
- 19 Nov 2019 Planned number of patients changed from 20 to 30.